title: Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.
abstract: Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA and subsequently, the CA improved and KD was controlled without complications 20 months after the onset.
authors.affiliation: Department of Pediatrics, Kochi National Hospital, Kochi, Japan.
authors.forename: Taku
authors.initials: T
authors.lastname: Oishi
authors.forename: Mikiya
authors.initials: M
authors.lastname: Fujieda
authors.forename: Taisuke
authors.initials: T
authors.lastname: Shiraishi
authors.forename: Miki
authors.initials: M
authors.lastname: Ono
authors.forename: Kazuo
authors.initials: K
authors.lastname: Inoue
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Takahashi
authors.forename: Hideo
authors.initials: H
authors.lastname: Ogura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wakiguchi
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003323:Coronary Aneurysm / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004351:Drug Resistance; D004452:Echocardiography; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D000069285:Infliximab; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab